Taro Pharmaceutical Industries Ltd. Ordinary Shares (TARO): Price and Financial Metrics


Taro Pharmaceutical Industries Ltd. Ordinary Shares (TARO)

Today's Latest Price: $67.45 USD

0.04 (-0.06%)

Updated Jul 2 4:10pm

Add TARO to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 214 in Medical - Pharmaceuticals

See all "A" rated Strong Buy stocks

TARO Stock Summary

  • Taro Pharmaceutical Industries Ltd's stock had its IPO on April 1, 1993, making it an older stock than 77.77% of US equities in our set.
  • The ratio of debt to operating expenses for Taro Pharmaceutical Industries Ltd is higher than it is for about merely 0.34% of US stocks.
  • TARO's equity multiplier -- a measure of assets relative to shareholders'equity -- is greater than that of merely 9.37% of US stocks.
  • Stocks with similar financial metrics, market capitalization, and price volatility to Taro Pharmaceutical Industries Ltd are OPTT, AMSC, CBLI, SPNS, and SCON.
  • Visit TARO's SEC page to see the company's official filings. To visit the company's web site, go to www.taro.com.
TARO Daily Price Range
TARO 52-Week Price Range

TARO Stock Price Chart Technical Analysis Charts


TARO Price/Volume Stats

Current price $67.45 52-week high $99.69
Prev. close $67.49 52-week low $56.07
Day low $67.36 Volume 21,429
Day high $68.11 Avg. volume 43,356
50-day MA $67.51 Dividend yield N/A
200-day MA $75.28 Market Cap 2.58B

Taro Pharmaceutical Industries Ltd. Ordinary Shares (TARO) Company Bio


Taro Pharmaceutical Industries offers prescription and over-the-counter pharmaceutical products focusing on primary areas, including topical creams and ointments, liquids, capsules, and tablets in the dermatological and topical, cardiovascular, neuropsychiatric, and anti-inflammatory therapeutic categories. The company was founded in 1959 and is based in Haifa Bay, Israel.

TARO Price Forecast Based on DCF Valuation

Current PriceDCF Fair Value Target:Forecasted Gain:
$67.45$32.85-51%

The table below illustrates the output of a discounted cash flow forecast using a variety of scenarios for Taro Pharmaceutical Industries Ltd. To summarize, we found that Taro Pharmaceutical Industries Ltd ranked in the 30th percentile in terms of potential gain offered. We should note, though, that the most conservative analysis suggests this stock will yield negative results -- and thus may be a potential short opportunity. In terms of the factors that were most noteworthy in this DCF analysis for TARO, they are:

  • In the past 4.97 years, Taro Pharmaceutical Industries Ltd has a compound free cash flow growth rate of -0.09%; that's higher than only 11.24% of free cash flow generating stocks in the Healthcare sector.
  • The business' balance sheet reveals debt to be 0% of the company's capital (with equity being the remaining amount). Approximately merely 0% of US stocks with free cash flow have a lower reliance on debt in their capital structure.
  • Taro Pharmaceutical Industries Ltd's interest coverage rate -- a measure of gross earnings relative to interest payments -- comes in at -5.14. This coverage rate is greater than that of only 11.29% of stocks we're observing for the purpose of forecasting via discounted cash flows.


Terminal Growth Rate in Free Cash FlowReturn Relative to Current Share Price
0%-52%
1%-52%
2%-51%
3%-51%
4%-50%
5%-50%

NUVA, BIO, ZBH, CAH, and IONS can be thought of as valuation peers to TARO, in the sense that they are in the Healthcare sector and have a similar price forecast based on DCF valuation.


TARO Latest News Stream


Event/TimeNews Detail
Loading, please wait...

TARO Latest Social Stream


Loading social stream, please wait...

View Full TARO Social Stream

Latest TARO News From Around the Web

Below are the latest news stories about Taro Pharmaceutical Industries Ltd that investors may wish to consider to help them evaluate TARO as an investment opportunity.

Hedge Funds Are Selling Taro Pharmaceutical Industries Ltd. (TARO)

The latest 13F reporting period has come and gone, and Insider Monkey is again at the forefront when it comes to making use of this gold mine of data. Insider Monkey finished processing 821 13F filings submitted by hedge funds and prominent investors. These filings show these funds' portfolio positions as of March 31st, 2020. […]

Yahoo | June 25, 2020

Taro Annual Report on Form 20-F Available for Fiscal Year Ended March 31, 2020

Taro Annual Report on Form 20-F Available for Fiscal Year Ended March 31, 2020

Yahoo | June 19, 2020

Taro Pharmaceutical Industries Ltd. to Host Earnings Call

NEW YORK, NY / ACCESSWIRE / May 20, 2020 / Taro Pharmaceutical Industries Ltd. (NYSE:TARO) will be discussing their earnings results in their 2019 Fourth Quarter Earnings call to be held on May 20, 2020 ...

Yahoo | May 20, 2020

Taro Pharmaceutical (TARO) Misses Q4 Earnings Estimates

Taro (TARO) delivered earnings and revenue surprises of -7.19% and 3.98%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

Zacks Investment Research | May 19, 2020

Taro Provides Results for the Year Ended March 31, 2020

Taro Provides Results for the Year Ended March 31, 2020

Yahoo | May 19, 2020

Read More 'TARO' Stories Here

TARO Price Returns

1-mo -1.22%
3-mo 6.72%
6-mo -23.98%
1-year -20.70%
3-year -41.34%
5-year -52.65%
YTD -23.29%
2019 3.89%
2018 -19.17%
2017 -0.53%
2016 -31.89%
2015 4.29%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.8319 seconds.